Jen So is an associate in the firm’s Business Law department and a member of its Life Sciences group. Jen focuses her practice on securities and corporate law. She counsels clients in compliance and reporting matters involving the U.S. Securities and Exchange Commission. She also represents clients on public and private offerings, venture financings and other complex transactions.
- Fulcrum Therapeutics in its $75 million follow-on offering, the establishment of a $50 million “at the market” offering facility and its universal shelf registration of up to $350 million of securities
- BridgeBio Pharma in its $275 million follow-on offering
- Absci in the maintenance of its $100 million “at the market” offering facility
- Magenta Therapeutics in its universal shelf registration of up to $250 million of securities and its business combination with Dianthus Therapeutics, Inc.
- The underwriters of Taysha Gene Therapies’ $75 million follow-on offering of common stock and pre-funded warrants
- The underwriters of Bionomics’ $23 million initial public offering of American Depositary Shares
- Calliditas Therapeutics in its universal shelf registration of American Depositary Shares and other securities
The financing and securitization of various asset classes, including automobile loans, automobile leases, dealer floorplan loans, Property Assessed Clean Energy (PACE) bonds, divorce loans and trade receivables.
Professional Experience
Prior to joining Goodwin in 2022, Jen was a legal counsel at eHealth, Inc.
After graduating from law school, Jen was an associate in the corporate departments of Mayer Brown LLP and Winston & Strawn LLP.
Credentials
Education
JD2008
University of California, Berkeley
(American Jurisprudence Award in Modern Financial Products)
MA2004
University of California, Los Angeles
BA2001
Stanford University
Admissions
Bars
- California